Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Taxotere
TAXOTERE 20 mg/0.5 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 11
HOS-084515 · Präparat HOS-083047
In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a
dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor
(see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with
the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
49%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ritonavir (HOS-084521) saquinavir (HOS-084522) telithromycin (HOS-084523) voriconazole (HOS-084524)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 564–1272 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 80 mg/2 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 55
HOS-084650 · Präparat HOS-083047
In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a
dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor
(see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with
the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
49%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517) indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ritonavir (HOS-084521) saquinavir (HOS-084522) telithromycin (HOS-084523) voriconazole (HOS-084524) ketoconazole (HOS-084513) itraconazole (HOS-084516)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 564–1272 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 20 mg/1 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 100
HOS-084764 · Präparat HOS-083047
In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a
dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor
(see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with
the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
49%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ritonavir (HOS-084521) saquinavir (HOS-084522) telithromycin (HOS-084523) voriconazole (HOS-084524)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 564–1272 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 80 mg/4 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 144
HOS-084876 · Präparat HOS-083047
In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a
dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor
(see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with
the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
49%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ritonavir (HOS-084521) saquinavir (HOS-084522) telithromycin (HOS-084523) voriconazole (HOS-084524)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 564–1272 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 160 mg/8 mL concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 189
HOS-084986 · Präparat HOS-083047
In case of combination with CYP3A4 inhibitors, the occurrence of docetaxel adverse reactions may
increase, as a result of reduced metabolism. If the concomitant use of a strong CYP3A4 inhibitor (e.g.,
ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a
dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor
(see section 4.4). In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with
the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
49%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) saquinavir (HOS-084522) telithromycin (HOS-084523) voriconazole (HOS-084524) nelfinavir (HOS-084520) ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) indinavir (HOS-084518) nefazodone (HOS-084519)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage f640897b581648a671549528599a0e77c0e915b1bc7804c45ad024fcf812c54f · Zeichen 564–1272 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11
HOS-086179 · Präparat HOS-083284
Medicinal Product Interactions – Ritonavir with Protease Inhibitors
Co-administered Dose of Co- Dose of Medicinal Product AUC Cmin
Medicinal Product administered NORVIR Assessed
Medicinal (mg)
Product
(mg)
Atazanavir 300 q24h 100 q24h Atazanavir ↑ 86% ↑ 11 fold
1
Atazanavir ↑ 2 fold ↑ 3-7 fold
Ritonavir increases the serum levels of atazanavir as a result of CYP3A4 inhibition.
Clinical trials confirmed the safety and efficacy of 300 mg atazanavir once daily with
ritonavir 100 mg once daily in treatment experienced patients. For further information,
physicians should refer to the SmPC for atazanavir.
Darunavir 600, single 100 q12h Darunavir ↑ 14 fold
Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition.
Darunavir must be given with ritonavir to ensure its therapeutic effect. Ritonavir doses
higher than 100 mg twice daily have not been studied with darunavir. For further
information, refer to the SmPC for darunavir.
Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 ↑ 11 fold
fold
Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of
CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its therapeutic
effect. Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice
daily with ritonavir 100 mg twice daily. Ritonavir doses higher than 100 mg twice daily
10
have not been studied with fosamprenavir. For further information, physicians should refer
to the SmPC for fosamprenavir.
Indinavir 800 100 q12h Indinavir2 ↑ 178% ND
q12h
Ritonavir ↑ 72% ND
Ritonavir increases the serum levels of indinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is
achieved with doses higher than 100 mg twice daily. In cases of co-administration of
ritonavir (100 mg twice daily) and indinavir (800 mg twice daily) caution is warranted as
the risk of nephrolithiasis may be increased.
Nelfinavir 1250 100 q12h Nelfinavir ↑ ND
q12h 20to39%
Ritonavir increases the serum levels of nelfinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is
achieved with doses higher than 100 mg twice daily.
Tipranavir 500 200 q12h Tipranavir ↑ 11 fold ↑ 29 fold
q12h
Ritonavir ↓ 40% ND
Ritonavir increases the serum levels of tipranavir as a result of CYP3A inhibition.
Tipranavir must be given with low dose ritonavir to ensure its therapeutic effect. Doses of
ritonavir less than 200 mg twice daily should not be used with tipranavir as they might alter
the efficacy of the combination. For further information, physicians should refer to the
SmPC for tipranavir.
ND: Not determined.
1. Based on cross-study comparison to 400 mg atazanavir once daily alone.
2. Based on cross-study comparison to 800 mg indinavir three times daily alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nelfinavir (HOS-084520) tipranavir (HOS-086184) amprenavir (HOS-086183) indinavir (HOS-084518) protease (HOS-085623) atazanavir (HOS-086180) darunavir (HOS-086181) fosamprenavir (HOS-086182)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 03a194213ac89748c50cfb4b51554f8455df8df904ff2077009223828e61e82e · Zeichen 2655–7456 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-086399 · Präparat HOS-083284
Co- Dose of Co- Dose of Medicinal Product AUC Cmin
administered administered NORVIR Assessed
Medicinal Medicinal Product (mg)
Product (mg)
Atazanavir 300 q24h 100 q24h Atazanavir ↑ 86% ↑ 11 fold
1
Atazanavir ↑ 2 fold ↑ 3-7
fold
Ritonavir increases the serum levels of atazanavir as a result of CYP3A4 inhibition. Clinical
trials confirmed the safety and efficacy of 300 mg atazanavir once daily with ritonavir 100 mg
once daily in treatment experienced patients. For further information, physicians should refer
to the SmPC for atazanavir.
Darunavir 600, single 100 q12h Darunavir ↑ 14 fold
Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition. Darunavir
must be given with ritonavir to ensure its therapeutic effect. Ritonavir doses higher than
100 mg twice daily have not been studied with darunavir. For further information, refer to the
SmPC for darunavir.
Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 ↑ 11 fold
fold
Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of
CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its therapeutic
effect. Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice daily
with ritonavir 100 mg twice daily. Ritonavir doses higher than 100 mg twice daily have not
been studied with fosamprenavir. For further information, physicians should refer to the
SmPC for fosamprenavir.
Indinavir 800 q12h 100 q12h Indinavir2 ↑ 178% ND
Ritonavir ↑ 72% ND
Ritonavir increases the serum levels of indinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved
with doses higher than 100 mg twice daily. In cases of co-administration of ritonavir (100 mg
twice daily) and indinavir (800 mg twice daily) caution is warranted as the risk of
nephrolithiasis may be increased.
Nelfinavir 1250 q12h 100 q12h Nelfinavir ↑ ND
20to39%
Ritonavir increases the serum levels of nelfinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved
with doses higher than 100 mg twice daily.
Tipranavir 500 q12h 200 Tipranavir ↑ 11 fold ↑ 29 fold
q12h
Ritonavir ↓ 40% ND
Ritonavir increases the serum levels of tipranavir as a result of CYP3A inhibition. Tipranavir
must be given with low dose ritonavir to ensure its therapeutic effect. Doses of ritonavir less
than 200 mg twice daily should not be used with tipranavir as they might alter the efficacy of
the combination. For further information, physicians should refer to the SmPC for tipranavir.
ND: Not determined.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tipranavir (HOS-086184) atazanavir (HOS-086180) darunavir (HOS-086181) fosamprenavir (HOS-086182) amprenavir (HOS-086183) indinavir (HOS-084518) nelfinavir (HOS-084520)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage d5308747ba178c6ebd0e34322c465d7122d5458d70aff134d17f324382a8fc16 · Zeichen 2732–7211 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-086400 · Präparat HOS-083284
1. Based on cross-study comparison to 400 mg atazanavir once daily alone.
2. Based on cross-study comparison to 800 mg indinavir three times daily alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) indinavir (HOS-084518)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 71fe7e533a1b113d7cbf463366af463ab42e4213a8966cd09c1bffbe648c857a · Zeichen 7235–7410 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10
HOS-090616 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) boceprevir (HOS-090617) telaprevir (HOS-090618) nicardipine (HOS-090619) bromocriptine (HOS-090620) cimetidine (HOS-085835) danazol (HOS-085473) letermovir (HOS-090621) clotrimazole (HOS-090574) fluconazole (HOS-087945) itraconazole (HOS-084516) voriconazole (HOS-084524) troleandomycin (HOS-090575) telithromycin (HOS-084523) clarithromycin (HOS-084517) protease (HOS-085623) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 5e78d73fd3b12aea3ede2eeac1a14a3dfb8e863d7c5ea6929177114d000b7a9c · Zeichen 5491–5914 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-090685 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, and telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517) protease (HOS-085623) ritonavir (HOS-084521) indinavir (HOS-084518) boceprevir (HOS-090617) telaprevir (HOS-090618) nicardipine (HOS-090619) bromocriptine (HOS-090620) cimetidine (HOS-085835) danazol (HOS-085473) letermovir (HOS-090621) clotrimazole (HOS-090574) fluconazole (HOS-087945) itraconazole (HOS-084516) voriconazole (HOS-084524) troleandomycin (HOS-090575) telithromycin (HOS-084523)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 238f7546225e192c0d4817ab6a1671062b9e93e1fd99e257fa0ce448f21b38a0 · Zeichen 5433–5860 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-109458 · Präparat HOS-093201
300 mg QD (coadministered Phenytoin Cmax 67% Phenytoin may be
with voriconazole 400 mg Phenytoin AUC 81% coadministered with
BID)* Compared to voriconazole 200 mg voriconazole if the maintenance
BID, dose of voriconazole is increased
Voriconazole Cmax 34% to 5 mg/kg IV BID or from
Voriconazole AUC 39% 200 mg to 400 mg oral BID
(100 mg to 200 mg oral BID in
patients less than 40 kg) (see
section 4.2).
12
Antidiabetics
Sulfonylureas (including but Although not studied, voriconazole Careful monitoring of blood
not limited to: tolbutamide, is likely to increase the plasma glucose is recommended. Dose
glipizide, glyburide) concentrations of sulfonylureas and reduction of sulfonylureas should
[CYP2C9 substrates] cause hypoglycaemia. be considered.
Anti-fungals
Fluconazole (200 mg QD) Voriconazole Cmax 57% The reduced dose and/or
[CYP2C9, CYP2C19 and Voriconazole AUC 79% frequency of voriconazole and
CYP3A4 inhibitor] Fluconazole Cmax ND fluconazole that would eliminate
Fluconazole AUC ND this effect have not been
established. Monitoring for
voriconazole-associated adverse
reactions is recommended if
voriconazole is used sequentially
after fluconazole.
Antihistamines
Astemizole Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
astemizole can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Terfenadine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
terfenadine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Anti HIV agents
Indinavir (800 mg TID) Indinavir Cmax ↔ No dose adjustment
[CYP3A4 inhibitor and Indinavir AUC ↔
substrate] Voriconazole Cmax ↔
Voriconazole AUC ↔
Ritonavir (protease inhibitor)
[potent CYP450 inducer;
CYP3A4 inhibitor and
substrate]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glipizide (HOS-109460) glyburide (HOS-109273) phenytoin (HOS-084531) tolbutamide (HOS-086568) glucose (HOS-088412) fluconazole (HOS-087945) astemizole (HOS-085608) lead (HOS-085592) terfenadine (HOS-085607) indinavir (HOS-084518) ritonavir (HOS-084521) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage c43ce720ce152b6ffc284ecb767edcbe81187c3aba91372adac27d1baca516f9 · Zeichen 11584–14886 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 44–45
HOS-109540 · Präparat HOS-093201
44
Terfenadine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
terfenadine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Anti HIV agents
Indinavir (800 mg TID) Indinavir Cmax ↔ No dose adjustment
[CYP3A4 inhibitor and Indinavir AUC ↔
substrate] Voriconazole Cmax ↔
Voriconazole AUC ↔
Ritonavir (protease inhibitor)
[potent CYP450 inducer;
CYP3A4 inhibitor and
substrate]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) terfenadine (HOS-085607) indinavir (HOS-084518) ritonavir (HOS-084521) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage f6a70c9142e2f517a32a7e0c09633e6caa907ecd38c03200c8d88f9a5a119b6e · Zeichen 14558–15283 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 76–77
HOS-109604 · Präparat HOS-093201
300 mg QD (coadministered Phenytoin Cmax 67% Phenytoin may be
with voriconazole 400 mg Phenytoin AUC 81% coadministered with
BID)* Compared to voriconazole 200 mg voriconazole if the maintenance
BID, dose of voriconazole is increased
Voriconazole Cmax 34% to 5 mg/kg IV BID or from
Voriconazole AUC 39% 200 mg to 400 mg oral BID
(100 mg to 200 mg oral BID in
patients less than 40 kg) (see
section 4.2).
76
Antidiabetics
Sulfonylureas (including but Although not studied, voriconazole Careful monitoring of blood
not limited to: tolbutamide, is likely to increase the plasma glucose is recommended. Dose
glipizide, glyburide) concentrations of sulfonylureas and reduction of sulfonylureas should
[CYP2C9 substrates] cause hypoglycaemia. be considered.
Anti-fungals
Fluconazole (200 mg QD) Voriconazole Cmax 57% The reduced dose and/or
[CYP2C9, CYP2C19 and Voriconazole AUC 79% frequency of voriconazole and
CYP3A4 inhibitor] Fluconazole Cmax ND fluconazole that would eliminate
Fluconazole AUC ND this effect have not been
established. Monitoring for
voriconazole-associated adverse
reactions is recommended if
voriconazole is used sequentially
after fluconazole.
Antihistamines
Astemizole Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
astemizole can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Terfenadine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of 4.3)
terfenadine can lead to QTc
prolongation and rare occurrences
of torsades de pointes.
Anti HIV agents
Indinavir (800 mg TID) Indinavir Cmax ↔ No dose adjustment
[CYP3A4 inhibitor and Indinavir AUC ↔
substrate] Voriconazole Cmax ↔
Voriconazole AUC ↔
Ritonavir (protease inhibitor)
[potent CYP450 inducer;
CYP3A4 inhibitor and
substrate]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) tolbutamide (HOS-086568) glucose (HOS-088412) glipizide (HOS-109460) glyburide (HOS-109273) fluconazole (HOS-087945) astemizole (HOS-085608) lead (HOS-085592) terfenadine (HOS-085607) indinavir (HOS-084518) ritonavir (HOS-084521) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage f19ccc38aa29c7c75168a00762b93a1ec1fb9ac13e31bd781df6a45a736467a1 · Zeichen 11616–14918 im Abschnitt
Wechselwirkungen · Glivec
Glivec 100 mg film-coated tablets Glivec 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-110215 · Präparat HOS-093339
Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors
such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole
antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such
as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib
concentrations. There was a significant increase in exposure to imatinib (the mean Cmax and AUC of
imatinib rose by 26% and 40%, respectively) in healthy subjects when it was co-administered with a
single dose of ketoconazole (a CYP3A4 inhibitor). Caution should be taken when administering
Glivec with inhibitors of the CYP3A4 family.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517) telithromycin (HOS-084523) protease (HOS-085623) indinavir (HOS-084518) lopinavir (HOS-086269) ritonavir (HOS-084521) saquinavir (HOS-084522) telaprevir (HOS-090618) nelfinavir (HOS-084520) boceprevir (HOS-090617) ketoconazole (HOS-084513) itraconazole (HOS-084516) posaconazole (HOS-085622) voriconazole (HOS-084524) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-12T09:28:00Z · SHA-256 838bc114dc50fcc5141e52ce7cbac64366b6fd4a03bb5a5e7a5ec09cf8be0b00 · Passage 8b33adeac7a33ce76a3ed583287cd02ab3b3048c12d43838a030dbd58a7f3ff4 · Zeichen 68–805 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20
HOS-110543 · Präparat HOS-093385
Studies conducted with other medicinal products
There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was
co-administered with emtricitabine, lamivudine, indinavir, efavirenz, nelfinavir, saquinavir (ritonavir
boosted), methadone, ribavirin, rifampicin, tacrolimus, or the hormonal contraceptive
norgestimate/ethinyl oestradiol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) emtricitabine (HOS-085840) lamivudine (HOS-085829) indinavir (HOS-084518) efavirenz (HOS-087947) nelfinavir (HOS-084520) saquinavir (HOS-084522) ritonavir (HOS-084521) methadone (HOS-086198) ribavirin (HOS-088127) tacrolimus (HOS-085202)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 83399d7c05202dd19f8869e7fff1b0b79c80c11ccfc6a80aadea42bad4cc1d9c · Zeichen 35885–36251 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 60
HOS-110635 · Präparat HOS-093385
Studies conducted with other medicinal products
There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was
co-administered with emtricitabine, lamivudine, indinavir, efavirenz, nelfinavir, saquinavir (ritonavir
boosted), methadone, ribavirin, rifampicin, tacrolimus, or the hormonal contraceptive
norgestimate/ethinyl oestradiol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) lamivudine (HOS-085829) indinavir (HOS-084518) efavirenz (HOS-087947) nelfinavir (HOS-084520) saquinavir (HOS-084522) ritonavir (HOS-084521) methadone (HOS-086198) ribavirin (HOS-088127) tacrolimus (HOS-085202) norgestimate (HOS-110544)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 83399d7c05202dd19f8869e7fff1b0b79c80c11ccfc6a80aadea42bad4cc1d9c · Zeichen 39159–39525 im Abschnitt
Wechselwirkungen · Viread
Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 100
HOS-110725 · Präparat HOS-093385
Studies conducted with other medicinal products
There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was
co-administered with emtricitabine, lamivudine, indinavir, efavirenz, nelfinavir, saquinavir (ritonavir
boosted), methadone, ribavirin, rifampicin, tacrolimus, or the hormonal contraceptive
norgestimate/ethinyl oestradiol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamivudine (HOS-085829) emtricitabine (HOS-085840) indinavir (HOS-084518) efavirenz (HOS-087947) nelfinavir (HOS-084520) saquinavir (HOS-084522) ritonavir (HOS-084521) methadone (HOS-086198) ribavirin (HOS-088127) tacrolimus (HOS-085202) norgestimate (HOS-110544)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 83399d7c05202dd19f8869e7fff1b0b79c80c11ccfc6a80aadea42bad4cc1d9c · Zeichen 39159–39525 im Abschnitt
Wechselwirkungen · Viread
Viread 245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 142
HOS-110816 · Präparat HOS-093385
Studies conducted with other medicinal products
There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was
co-administered with emtricitabine, lamivudine, indinavir, efavirenz, nelfinavir, saquinavir (ritonavir
boosted), methadone, ribavirin, rifampicin, tacrolimus, or the hormonal contraceptive
norgestimate/ethinyl oestradiol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) lamivudine (HOS-085829) indinavir (HOS-084518) efavirenz (HOS-087947) nelfinavir (HOS-084520) saquinavir (HOS-084522) ritonavir (HOS-084521) methadone (HOS-086198) ribavirin (HOS-088127) tacrolimus (HOS-085202) norgestimate (HOS-110544)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 83399d7c05202dd19f8869e7fff1b0b79c80c11ccfc6a80aadea42bad4cc1d9c · Zeichen 39235–39601 im Abschnitt
Wechselwirkungen · Viread
Viread 33 mg/g granules · Abschnitt 4.5 · PDF-Seite 184
HOS-110912 · Präparat HOS-093385
Studies conducted with other medicinal products
There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was
co-administered with emtricitabine, lamivudine, indinavir, efavirenz, nelfinavir, saquinavir (ritonavir
boosted), methadone, ribavirin, rifampicin, tacrolimus, or the hormonal contraceptive
norgestimate/ethinyl oestradiol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) methadone (HOS-086198) ribavirin (HOS-088127) nelfinavir (HOS-084520) saquinavir (HOS-084522) emtricitabine (HOS-085840) lamivudine (HOS-085829) indinavir (HOS-084518) efavirenz (HOS-087947) tacrolimus (HOS-085202) norgestimate (HOS-110544)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 83399d7c05202dd19f8869e7fff1b0b79c80c11ccfc6a80aadea42bad4cc1d9c · Zeichen 36283–36649 im Abschnitt
Gegenanzeigen · Levitra
Levitra 5 mg film-coated tablets Levitra10 mg film-coated tablets Levitra 20 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-111583 · Präparat HOS-093557
Concomitant use of vardenafil with HIV protease inhibitors such as ritonavir and indinavir is
contraindicated, as they are very potent inhibitors of CYP3A4 (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) ritonavir (HOS-084521) indinavir (HOS-084518)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-20T02:00:00Z · SHA-256 47e3580d78a6f70de1b067c00d9d64bdf57d13d70ada7a3e149ededb018a79a5 · Passage 8e938e43ff862fbb6c16818acd62239ba4cf3a16aacde3d1485a3a1dd7edb331 · Zeichen 1469–1643 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.